1. Scrip
  2. >>Business
  3. >>Earnings

CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus

More Jobs, Cost Cuts Bring Year’s Total To $1bn

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

A double wooden door chained closed
Biogen is shutting down nearly all Aduhelm commercial operations • Source: Shutterstock

CEO Michel Vounatsos opened Biogen, Inc.’s 3 May first quarter earnings call by acknowledging that he has led the company, and is leaving it, during a challenging period. Key among those challenges is the failed commercialization of Alzheimer’s treatment Aduhelm (aducanumab) – a launch that the company has now essentially shut down – which was widely expected to reverse the significant revenue declines that began during the current CEO’s tenure.

Vounatsos will remain at the helm until the board of directors completes its search for a new CEO, though the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.